We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: GLP-1RA
MedXY News
EnglishTag

GLP-1RA

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits
CardiologyGLP-1RAHội Chứng CKM

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits

By MedXY|Mar 28, 2026

This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.

The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation
CardiologyGLP-1RAHội Chứng CKM

The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation

By MedXY|Mar 18, 2026

This review synthesizes population-level data on the eligibility for GLP-1RAs, SGLT2is, and nsMRAs, highlighting that over 60% of US adults meet indications for these transformative therapies.

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes: A Comparative Effectiveness Review
Clinical Updateschronic kidney diseaseGLP-1RA

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes: A Comparative Effectiveness Review

By MedXY|Mar 15, 2026

This review synthesizes evidence comparing SGLT2 inhibitors and GLP-1 receptor agonists, highlighting a significant reduction in chronic kidney disease and acute kidney injury risks associated with SGLT2i initiation.

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events
Cardiologycardiovascular diseaseGLP-1RA

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

By MedXY|Mar 12, 2026

This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% re

Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors
Clinical UpdatesGLP-1RAheart failure

Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors

By MedXY|Mar 2, 2026

A large-scale target trial emulation demonstrates that GLP-1RAs significantly reduce heart failure hospitalization risks compared to DPP-4 inhibitors and provide comparable protection to SGLT-2 inhibitors in routine clinical practice.

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data
Diabetes & EndocrinologyGLP-1RAliver fibrosis

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data

By MedXY|Nov 23, 2025

A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study
Cardiologycardiovascular outcomesGLP-1RA

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

By MedXY|Nov 7, 2025

In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults an

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities